DNLI Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Denali Therapeutics's net margin of --. Denali Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Denali Therapeutics has a consensus price target of $32.19, signalling upside risk potential of 129.91%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 275%. Given that Armata Pharmaceuticals has higher upside potential than Denali Therapeutics, analysts believe Armata Pharmaceuticals is more attractive than Denali Therapeutics.

Denali Therapeutics has a beta of 1.330, which suggesting that the stock is 32.997% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Denali Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Denali Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Denali Therapeutics's net income of -$133M is lower than Armata Pharmaceuticals's net income of -$6.5M. Notably, Denali Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics is 6.98x versus 1,002.10x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Denali Therapeutics's net margin of --. Denali Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Denali Therapeutics has a consensus price target of $32.19, signalling upside risk potential of 129.91%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 235.88%. Given that Perspective Therapeutics has higher upside potential than Denali Therapeutics, analysts believe Perspective Therapeutics is more attractive than Denali Therapeutics.

Denali Therapeutics has a beta of 1.330, which suggesting that the stock is 32.997% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Denali Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Denali Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Denali Therapeutics's net income of -$133M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Denali Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics is 6.98x versus 29.60x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Denali Therapeutics's net margin of 12.06%. Denali Therapeutics's return on equity of -- beat Electromed's return on equity of 16.57%.

Denali Therapeutics has a consensus price target of $32.19, signalling upside risk potential of 129.91%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 83.76%. Given that Denali Therapeutics has higher upside potential than Electromed, analysts believe Denali Therapeutics is more attractive than Electromed.

Denali Therapeutics has a beta of 1.330, which suggesting that the stock is 32.997% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Denali Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Denali Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. Denali Therapeutics's net income of -$133M is lower than Electromed's net income of $1.9M. Notably, Denali Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 23.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics is 6.98x versus 2.66x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Denali Therapeutics's net margin of -35.79%. Denali Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

Denali Therapeutics has a consensus price target of $32.19, signalling upside risk potential of 129.91%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 865.52%. Given that Protalix BioTherapeutics has higher upside potential than Denali Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Denali Therapeutics.

Denali Therapeutics has a beta of 1.330, which suggesting that the stock is 32.997% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Denali Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Denali Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Denali Therapeutics's net income of -$133M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Denali Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 36.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics is 6.98x versus 2.03x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.